Difference between revisions of "Altretamine (Hexalen)"
Jump to navigation
Jump to search
m |
|||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
Class/mechanism: Alkylating-like, exact mechanism unknown—can form covalent adducts with tissue macromolecules including DNA.<ref name="insert">[http://us.eisai.com/pdf_files/hexalen_pi.pdf Altretamine (Hexalen) package insert]</ref><ref>[[Media:Altretamine.pdf | Altretamine (Hexalen) package insert (locally hosted backup)]]</ref> | Class/mechanism: Alkylating-like, exact mechanism unknown—can form covalent adducts with tissue macromolecules including DNA.<ref name="insert">[http://us.eisai.com/pdf_files/hexalen_pi.pdf Altretamine (Hexalen) package insert]</ref><ref>[[Media:Altretamine.pdf | Altretamine (Hexalen) package insert (locally hosted backup)]]</ref> | ||
| Line 14: | Line 12: | ||
*[http://chemocare.com/chemotherapy/drug-info/altretamine.aspx Altretamine (Hexalen) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/altretamine.aspx Altretamine (Hexalen) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/chemotherapy/drug-info/altretamine.aspx Altretamine (Hexalen) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/altretamine.aspx Altretamine (Hexalen) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/altretamine-patient-drug-information Altretamine (Hexalen) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/altretamine-patient-drug-information Altretamine (Hexalen) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/altretamine-patient-drug-information Altretamine (Hexalen) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/altretamine-patient-drug-information Altretamine (Hexalen) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *12/26/1990: Initial FDA approval | ||
| + | |||
| + | ==Also known as== | ||
| + | Hexamethylmelamine or HMM. | ||
==References== | ==References== | ||
| Line 22: | Line 26: | ||
[[Category:Alkylating agents]] | [[Category:Alkylating agents]] | ||
[[Category:Ovarian cancer medications]] | [[Category:Ovarian cancer medications]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 1990]] | ||
Revision as of 16:31, 24 October 2014
General information
Class/mechanism: Alkylating-like, exact mechanism unknown—can form covalent adducts with tissue macromolecules including DNA.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Altretamine (Hexalen) patient drug information (Chemocare)[3]
- Altretamine (Hexalen) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 12/26/1990: Initial FDA approval
Also known as
Hexamethylmelamine or HMM.